TP53 and neoplasm: In the in vivo studies, our results show that the efficiency was about 19 % less (53.4 % vs. 72.3 % inhibition) in case of tumours bearing HCT116 p53 −/− cells as compared to HCT116 cells for DAT1 treatment of 20 mg/kg (Fig. 6b).